

RESEARCH

Open Access



Uterine smooth muscle tumors of uncertain malignant potential: a retrospective evaluation of clinical pathology and immunohistochemistry features

Mojgan Akbarzadeh-Jahromi¹, Nafiseh Todarbary², Fatemeh Sari Aslani¹, Fatemehsadat Najib³, Marjan Zare⁴ and Fatemeh Amirmoezi^{5*} 

Abstract

Background Uterine smooth muscle tumor of uncertain malignant potential (STUMP) is a group of uterine smooth muscle tumors which cannot be classified as a subtype of leiomyoma or leiomyosarcoma. Diagnosis, prognosis, and treatment of these tumors are challenging due to recurrence, potential of malignancy, and metastasis.

Methods A retrospective cohort study was conducted in southern Iran during 2011 to 2020. We included records of 21 patients with STUMP and 24 patients with leiomyoma by simple randomized sampling in the tertiary health care centers in Shiraz, southern Iran. Slides were reviewed by an expert pathologist for examining mitosis, necrosis, and atypia, and also proper blocks were selected for immunohistochemistry (IHC) staining.

Results From 45 participants, 21 (46.7%) and 24 (53.3%) patients were in the STUMP and normal leiomyoma groups, respectively. Odds ratio and 95% confidence interval (OR (95% C.I)) of pathologic size in the range of 5–10 cm was significantly higher in the STUMP group compared with normal leiomyoma. (CI: 7.22 (1.44–36.22)). Additionally, hyaline necrosis 0.05 (0.0–0.91), mild to moderate atypia 0.02 (0.0–0.4), moderate to severe atypia 0.01 (0.0–0.22), focal atypia 0.01 (0–0.26) and diffuse atypia 0.01 (0–0.26) were significantly fewer in normal leiomyoma compared to the STUMP group. Negative P16 0.01 (0.0007–0.24) and negative Bcl2 0.22 (0.06–0.81) were significantly higher in the normal leiomyoma group compared with the STUMP group. The cut-off points for predicting STUMP were 2.5% (sensitivity = 62% and specificity = 100%) and 45% (sensitivity = 43% and specificity = 96%) for P16 and bcl2, respectively.

Conclusion The category and management of STUMP continues to progress. The diagnosis for STUMP mainly depends on the histopathological manifestations. No single IHC marker such as P53, P16, and Bcl-2 has proved robust enough in separating STUMP from other leiomyoma variants; however, according to our study, we suggest combination use of P16 and Bcl-2 (cut off 2.5 and 45%, respectively) to distinguish equivocal cases of STUMP.

Keywords Uterine smooth muscle tumor of uncertain malignant potential (STUMP), Immunohistochemistry (IHC), Leiomyoma, P16, Bcl-2, P53

*Correspondence:
Fatemeh Amirmoezi
f_amirmoezi@yahoo.com
Full list of author information is available at the end of the article



studies revealed that presentation of Bcl-2 was more frequent and stronger in leiomyoma cases in comparison to STUMP and leiomyosarcoma [16, 18, 29, 37]. However, it can be used as a good prognostic marker to distinguish benign and malignant smooth muscle tumors. Despite the differences in presentation of Bcl-2 in leiomyosarcoma, leiomyoma and STUMP cases, it cannot be an exclusive diagnostic tool in this field.

Conclusion

The category and management of STUMP continues to progress. The diagnosis for STUMP mainly depends on the histopathological manifestations. No single IHC marker such as P53, P16, and Bcl-2 has proved robust enough in separating STUMP from other leiomyoma variants; however, according to our study, we suggest combined use of P16 and Bcl-2 (cut off 2.5 and 45%, respectively) to distinguish the equivocal cases of STUMP that are larger than 5 cm with at least moderate atypia and hyaline necrosis.

Abbreviations

AUB	Abnormal uterine bleeding
BSO	Bilateral salpingectomy
IHC	Immunohistochemistry
LDH	Lactate dehydrogenase
PMHx	Past medical history
STUMP	Smooth muscle tumors of uncertain malignant potential
TAH	Trans-abdominal hysterectomy
USO	Unilateral salpingectomy

Acknowledgements

The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran and also Center for Development of Clinical Research of Nemazee Hospital and Dr. Nasrin Shokrpour for editorial assistance.

Authors' contributions

MAJ, FSA and FN designed and MAJ conducted the study. MAJ and FA reviewed pathology slides. MZ analysed and interpreted the patients' data. FA and NT contributed in writing and editing the manuscript. FA and MAJ read and approved the final manuscript.

Funding

This article was extracted from the thesis written by Nafiseh Tadarbary and was financially supported by Research Dean of Shiraz University of Medical Sciences grants No.22538.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Maternal-fetal Medicine Research Center, Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. ²School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. ³Infertility Research Center, Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran. ⁴Maternal-fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ⁵Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Received: 25 May 2023 Accepted: 8 February 2024

Published online: 07 March 2024

References

1. Yordanov AD, Tantchev L, Vasileva P, Strashilov S, Vasileva-Slaveva M, Konsoulova A. Uterine smooth muscle tumours of uncertain malignant potential: single-centre experience and review of the literature. *Prz Menopauzalny*. 2020;19(1):30–4.
2. Picerno TM, Wasson MN, Gonzalez Rios AR, Zuber MJ, Taylor NP, Hoffman MK, et al. Morcellation and the incidence of Occult Uterine Malignancy: A Dual-Institution Review. *Int J Gynecol Cancer*. 2016;26(1):149–55.
3. Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. *Int J Gynaecol Obstet*. 2020;149(1):3–9.
4. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. *BJOG*. 2017;124(10):1501–12.
5. Jang TK, Kwon SH, Cho CH, Lee HW, Shin SJ. Giant uterine mass with uterine smooth muscle tumor of uncertain malignant potential: a case report. *Gynecol Oncol Rep*. 2020;34:100663.
6. Porter AE, Kho KA, Gwin K. Mass lesions of the myometrium: interpretation and management of unexpected pathology. *Curr Opin Obstet Gynecol*. 2019;31(5):349–55.
7. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. *Am J Surg Pathol*. 1994;18(6):535–58.
8. Cree IA. WHO Classification of Tumours, Female Genital tumours; 5th ed. 2020. 4:279–80.
9. Gupta M, Laury AL, Nucci MR, Quade BJ. Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. *Histopathology*. 2018;73(2):284–98.
10. Ip PP, Tse KY, Tam KF. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. *Adv Anat Pathol*. 2010;17(2):91–112.
11. Gadducci A, Zannoni GF. Uterine smooth muscle tumors of unknown malignant potential: a challenging question. *Gynecol Oncol*. 2019;154(3):631–7.
12. Rizzo A, Ricci AD, Saponara M, Perrone ADEL. Recurrent uterine smooth-muscle tumors of Uncertain Malignant potential (STUMP): state of the art. *Anticancer Res*. 2020;40(3):1229–38.
13. Manxhuka-Kerliu S, Kerliu-Saliu I, Sahatciu-Meka V, Kerliu L, Shahini L. Atypical uterine leiomyoma: a case report and review of the literature. *J Med Case Rep*. 2016;10:22.
14. Conconi D, Chiappa V, Perego P, Redaelli S, Bovo G, Lavitrano M, et al. Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential. *Oncol Rep*. 2017;37(1):41–7.
15. O'Neill CJ, McBride HA, Connolly LE, McCluggage WG. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. *Histopathology*. 2007;50(7):851–8.
16. Atkins KA, Arronte N, Darus CJ, Rice LW. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. *Am J Surg Pathol*. 2008;32(1):98–102.
17. Hewedi IH, Radwan NA, Shash LS. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors. *Diagn Pathol*. 2012;7:1.